FDA Clears Class II Status for Hyperhidrosis Skin Patch
Published Date: 6/30/2026
Rule
Summary
The FDA is officially classifying the skin patch that treats excessive sweating (hyperhidrosis) as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this cool new treatment faster and safer, starting June 30, 2026. Companies making these patches will find it easier and less costly to bring their products to market.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Skin Patch Reclassified to Class II
The FDA officially classified the skin patch for treating hyperhidrosis as a Class II device with special controls, effective June 30, 2026 (classification applicable April 7, 2023). FDA says this lower-classification reduces regulatory burdens and will enhance patients' access to the treatment.
De Novo Creates Easier Path For Firms
FDA used the De Novo process for the N-SWEAT Patch, which means that this device type can serve as a predicate for future devices so other sponsors may use the less-burdensome 510(k) pathway instead of De Novo or premarket approval. FDA issued the De Novo order April 7, 2023 and this classification is codified effective June 30, 2026.
Premarket 510(k) Requirement Remains
FDA states that skin patches for treatment of hyperhidrosis are subject to premarket notification under section 510(k) of the FD&C Act because FDA has not exempted this device type under section 510(m).
Required Safety, Testing, and Labeling Rules
FDA lists special controls that manufacturers must meet: clinical performance testing (including validated measures of reduction in hyperhidrosis and adverse events), non-clinical thermal and performance testing, biocompatibility, shelf-life testing, and patient and physician labeling that lists risks, duration of effect, disposal instructions, and a shelf life.
Device Is Prescription-Only
At the time of classification, FDA identifies skin patches for hyperhidrosis as prescription topical patches only. That means you must obtain a prescription from a clinician to use this device.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
Previous / Next Documents
Previous: 2026-13137 — Marine Casualty Reporting on the Outer Continental Shelf
Starting July 30, 2026, companies working on the Outer Continental Shelf must report marine accidents based on who’s involved, not just where they happen. The rule raises the damage cost that triggers a report from $25,000 to $75,000, saving businesses money and making rules clearer and fairer. This change cuts industry costs by over $10,000 in 10 years and aligns U.S. rules with international standards for offshore activities.
Next: 2026-13140 — Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of Oxygenation
The FDA is officially putting the monitor for opioid-induced oxygen problems into a safer, easier-to-manage category called Class II. This change helps make sure the device works well and is safe, while also speeding up patient access to this important tech. The new rules took effect on June 30, 2026, and could lower costs and delays for companies making these monitors.